

**This item is the archived peer-reviewed author-version of:**

Immunotherapy : is a minor god yet in the pantheon of treatments for lung cancer?

**Reference:**

Rolfo Christian, Sortino Giovanni, Smits Evelien, Janssens Annelies, Pauwels Patrick, et al.- Immunotherapy : is a minor god yet in the pantheon of treatments for lung cancer?

Expert review of anticancer therapy - ISSN 1473-7140 - 14:10(2014), p. 1173-1187

DOI: <http://dx.doi.org/doi:10.1586/14737140.2014.952287>

Handle: <http://hdl.handle.net/10067/1191550151162165141>

## **REVIEW ARTICLE**

### **TITLE: Immunotherapy: is a minor god yet in the pantheon of treatments for Lung Cancer?**

#### **AUTHORS:**

**Christian Rolfo<sup>1</sup>, Giovanni Sortino<sup>2</sup>, Evelien Smits<sup>3</sup>, Francesco Passiglia<sup>1,2</sup>, Giuseppe Bronte<sup>2</sup>, Marta Castiglia<sup>4,2</sup>, Antonio Russo<sup>2</sup>, Edgardo S. Santos<sup>5</sup>, Annelies Janssens<sup>6</sup>, Patrick Pauwels<sup>4</sup> & Luis Raez<sup>7</sup>.**

<sup>1</sup> Phase I - Early Clinical Trials Unit, Oncology Department, Antwerp University Hospital, Edegem, Belgium.

<sup>2</sup> Department of Surgical, Oncological and Stomatological Sciences, Section of Medical Oncology, University of Palermo, Italy.

<sup>3</sup> Tumor Immunotherapy Laboratory, Oncology Department, Antwerp University Hospital, Edegem, Belgium.

<sup>4</sup> Molecular Pathology Unit, Pathology Department, Antwerp University Hospital, Edegem, Belgium

<sup>5</sup> Thoracic and Head and Neck Cancer Programs, Lynn Cancer Institute/Boca Raton Regional Hospital, Boca Raton, Florida, USA

<sup>6</sup> Thoracic Oncology Cluster, Multidisciplinary Oncology Center of Antwerp, Antwerp University Hospital, Edegem, Belgium

<sup>7</sup> Thoracic Oncology Program, Memorial Cancer Institute, Memorial Health Care System, Pembroke Pines, FL, USA

#### **Corresponding author:**

Prof. Dr. Christian Rolfo  
Head of Phase I - Early Clinical Trials Unit  
Oncology Department  
Antwerp University Hospital  
Wilrijkstraat 10, 2650 Edegem, Belgium  
[Christian.rolfo@uza.be](mailto:Christian.rolfo@uza.be)  
Tel: +3238213646  
Fax: +3238251592

#### **Keywords:**

Non small cell lung cancer, Immunotherapy, Vaccines, Belagenpumatucel-L, GVAX, MAGE-A3, Tecemotide, CIMAvax, TG4010, Racotumomab, Ipilimumab, PD-1, PD-L1

## **TABLE OF CONTENTS**

1. Abstract
  2. Introduction
  3. Cancer immune-features and immunoediting
  4. Immunity in NSCLC
  5. Immunotherapeutic strategies for cancer
  6. Vaccines for NSCLC
    - 6.1 Whole cell vaccines
      - 6.1.1 Belagenpumatucel
      - 6.1.2 GVAX
    - 6.2 peptides e protein vaccines
      - 6.2.1 MAGE-A3/vaccine
      - 6.2.2 MUC1 and L-BLP25 (Tecemotide)
      - 6.2.3 EGF Vaccine: CIMAvax
    - 6.3 Viral vector vaccines: TG4010
    - 6.4 Ganglioside vaccines: Racotumomab
  7. Immunomodulators
    - 7.1 CTLA-4 inhibitor: Ipilimumab in Lung Cancer
    - 7.2 Anti-PD-1 Antibodies
    - 7.3 Anti-PD-L1 Antibodies
  8. Expert Commentary
  9. Five year view
  10. Conclusions
-

## **1. Abstract**

Immunotherapy has been studied for many years in lung cancer without significant results, making the majority of oncologists quite skeptical about its possible application for non-small cell lung cancer (NSCLC) treatment. However, the recent knowledge about immune escape and subsequent “cancer immunoediting” has yielded the development of new strategies of cancer immunotherapy, heralding a new era of lung cancer treatment. Cancer vaccines, including both whole cell and peptide vaccines have been tested both in early and advanced stages of NSCLC. New immunomodulators agents, including anti-CTLA4, anti-PD1/PDL1 monoclonal antibodies, have been investigated as monotherapy in metastatic lung cancer. To date, these treatments have shown impressive results of efficacy and tolerability in early clinical trials, leading to testing in several large, randomized, phase III trials. As these results will be confirmed, these drugs will be available in the near future, offering a new exciting therapeutic options for lung cancer treatment.

## **2. Introduction**

Despite several advances in lung cancer translational research, the survival outcomes for the majority of NSCLC patients remain still very poor [1, 2]. Recently, the introduction of targeted therapies, including EGFR tyrosine kinase inhibitors (erlotinib, gefitinib, afatinib) for EGFR mutated tumors, and EML4-ALK inhibitors (crizotinib, ceritinib) for ALK-rearranged tumors, significantly improved both median progression-free survival (PFS) and Quality of life (QoL) of metastatic NSCLC patients. [3]. However, these personalized treatment options are limited to a minority of NSCLC patients, whose tumors report the target activating mutations, while platinum-based doublet chemotherapy remains the unique choice for the majority of them. Therefore, the need for additional therapeutic options is widely shared in the scientific community. A promising field of research in oncology is represented by immunotherapy, which has been demonstrated to be a valid and effective treatment option for some other malignancies such as melanoma and prostate cancer [4, 5]. The rationale of studying immunotherapy for lung cancer comes from the possibility of enhancing a non-efficient or inhibited immune response against cancer cells. A better understanding of the expression of tumor-specific peptides, and the functional defects in immune pathways that allow tumors to escape immune-recognition/killing, has led to the development of new immunotherapeutic strategies with promising activity in the clinical setting. This review provides the biological basis for immunotherapy in NSCLC focusing on the new emerging immunotherapeutic agents currently under investigation in clinical trials.

## **3. Cancer immune-features and immunoediting**

The immune response to cancer involves both innate and adaptive compartments. Mechanisms are not fully known but they could be explained as follows. In the complex system of immune response to cancer, called immunoediting, three phases have been identified: elimination, equilibrium and escape (fig.1). In the first two phases (elimination and equilibrium) T-lymphocytes play the principal role and as result of their activation, the immune system is able to recognize and eliminate cancer cells. In the escape phase, malignancies become clinically relevant because they bypass the immune system's control by suppressing it [6]. In the first phase, tumor's growth induces the release of cytokines which activate cells of the innate

compartment (NK,  $\gamma\delta$ -cells and macrophages) and make them interact with cancer's surface destroying its cells. [7] Dendritic cells (DCs) are called antigen-presenting cells (APCs) because they are able to internalize and process tumor antigens, and to present them as small fragmented peptides linked to class I and II major histocompatibility complex (MHC) proteins. Activated DCs migrate to regional lymph nodes where they interact with naïve T-cells; this results into activation of cancer-specific Th1 (CD4) lymphocytes which are responsible for strengthening the immune response by the recruitment of CD8+ T-cells activated into cytotoxic T-lymphocytes (CTL). Then cancer-specific Th1 CD4+ and CD8+ lymphocytes migrates in the cancer site and kill its cells. [8] The presence of a lymphocytic infiltrate within the tumor masses is considered in fact, the direct evidence of the activity of the immune system against malignant tumors and in some cases, such as ovarian cancer, this seems to have a correlation with prognosis. [9] In the phase called equilibrium, which can last for years, various tumor cell clones grow and accumulate mutations thus exposing the immune system to different antigenic phenotypes. These changes determine an alternation of death and cell proliferation in the tumor and, in this phase, the disease is not yet evident. In the last stage so-called escape, cancer cells become able to evade the immune system. Immunotolerance can be induced through various mechanisms such as the activation of a class of T-lymphocytes with immune-suppressive functions (T-reg) or tumor's production of inhibiting cytokines such as IL-10 and TGF- $\beta$ . [10] A downregulation of NK activators such as NKG2D, overexpression of CD46, CD55 and CD59, and a reduced expression of class I MHC proteins are also implicated. [11-13] An altered expression of proteins that normally regulate a Fas-induced apoptosis mediated by NKs or CTLs (i.e. downregulation of Fas receptors and the secretion of Fas ligand), is another possible mechanism involved in immunotolerance to cancer. [14, 15]

#### **4. Immunity in NSCLC**

NSCLC has been considered a non-immunogenic malignancy for years and this opinion probably has addressed the choice of research fields. [16] In fact, data from the analysis of NSCLC tissues indicate that an immune reaction is present but also that the local immunosuppressive compartment limits its efficacy in controlling the tumor growth. [17] The presence of an intratumoral lymphocytic infiltrate has been demonstrated to have a positive prognostic significance also in NSCLC [18, 19] while a high number of Treg cells in the tumor (e.g., squamous NSCLC patients) seems to

be correlated with a high risk of recurrence. [20] Various antigens have been found in NSCLC and classified into diverse classes like cancer testis antigens, (MAGE-A3 and NY-ESO-1) expressed by squamous NSCLC cells and silent in normal tissues. [21] Moreover, gene mutations in cancer cells may produce mutated proteins which are exclusively expressed by tumors and function as tumor associated antigens (TAAs). In fact, CTLs directed against mutated antigens have been found in NSCLC patients. [22, 23] Some differences have been described between squamous and non-squamous NSCLC in terms of immunogenic profiles. Squamous-cell carcinoma expresses a multitude of molecules such as p63/CK5/6/34bE-12 while does not express TTF-1. Adenocarcinoma is instead characterized by a wider molecular heterogeneity. [24] Differences in antigen expression have been shown in several studies. For example, melanoma-associated antigen (MAGE)-A3, MAGE-A4 and NY-ESO-1, are more frequently expressed in squamous NSCLC than in non-squamous histology. [25, 26] These data constitute the conceptual basis to suppose that manipulation of the immune system may be a viable treatment option for NSCLC.

## **5. Immunotherapeutic strategies for cancer**

In a systematic classification of the possible strategies to improve the immune response against cancer and NSCLC, we can consider two different ways: enhancing immune stimulating components to start or maintain an effective response or inhibiting suppressing factors that block the immune response. [27] We can produce a positive effect on the immune system through two main strategies. The first is the administration of immunoglobulins directed against target-related antigens, which induce in the host a passive immunization. This kind of immunization is known to confer a rapid protection and it is usually administered to immunocompromised patients. The second strategy confers an active and durable immunization through the administration of antigens which activates the host's immune system. In anti-cancer therapy, active immunization can be obtained by the creation of cancer-specific vaccines which are able to induce the activation of CD4+ and CD8+ T-lymphocytes and secretion of specific immunoglobulins against TAAs. In fact, anti-cancer vaccines can be intended as a class of preparates containing TAAs administered as peptides, recombinant proteins, gangliosides or whole tumor cells, combined with an adjuvant, which are able to induce an active antitumor immunity in the host. [28] Another possible way is to modulate the immune system in a non-antigen-mediated way with the use of immunomodulators. For example, the

administration of immunostimulating cytokines, such as IL-2 or IFN- $\alpha$  or the use of inhibitors which block T-reg cell functions.

## **6. Vaccines for NSCLC**

### **6.1 Whole cell vaccines**

#### **6.1.1: Belagenpumatucel-L**

Belagenpumatucel-L is an allogeneic whole cell vaccine produced with four cell lines deriving from three different histologic types of NSCLC (one large cell carcinoma, one squamous cell carcinoma, and two adenocarcinoma) whose DNA have been modified through the transfection of a plasmid containing the TGF- $\beta$ 2 antisense transgene, which determines the downregulation of TGF- $\beta$ 2. TGF- $\beta$  is considered as an anti-inflammatory cytokine which can suppress the activity of NK cells, CTLs, and APC-cells, determining a blockade of the anti-cancer activity of the immune system. TGF- $\beta$  also works inducing FOXP3 and thus, converting CD4+ T-lymphocytes cells into T-reg cells with immunosuppressive activity. Moreover, a high TGF- $\beta$ 2 level seems to be associated with a poorer prognosis in NSCLC patients. [29] Belagenpumatucel-L has been studied by Nemunaitis et al., in a phase II dose variation trial in which 75 NSCLC patients with stage II, IIIA, IIIB, and IV disease were randomized to receive 1.25, 2.5 or 5.0  $\times 10^7$  cells/injection of the investigational drug administered with a monthly or every other month schedule, up to a total of 16 doses. [29] 81% of the patients enrolled had a non-resectable or metastatic disease and the 15% of the assessable cases showed a partial response to Belagenpumatucel-L. An important finding of the trial was the survival rate which seems to be dose-related; those patients who received the dosage of  $\geq 2.5 \times 10^7$  cells/injection showed an improvement in OS rate of 47% while for those receiving 1.25  $\times 10^7$  cells/injection the survival rate was 18%. A subgroup analysis of this study performed by Fakhrai H et al, led to demonstrate a correlation between the presence of a combined cellular and humoral immune responses and an improvement in OS in patients treated with belagenpumatucel-L. Patients with both types of responses, defined immune-response positive (n=11), obtained in fact an advantage in terms of median OS compared to those patients (n=24) who were defined as immune response-negative (32.5m 95% CI: 25.2–39.8 vs 11.6m 95% CI: 5.6–17.6; p = 0.011). They suggested that the activity of both immune system compartments is critical for the induction of a clinically significant antitumor immunity by this vaccine. Only one grade 3 toxicity has been registered and the drug

had a good safety profile. [30] Based on these promising data, the phase III placebo-controlled, randomized, multinational STOP trial has evaluated the treatment with belagenpumatucel-L as maintenance therapy for IIIA, IIIB, and IV NSCLC patients who did not progress after front-line chemotherapy and randomized between 4 and 17.4 weeks from the end of chemotherapy. A total of 532 eligible patients were enrolled (42 stage IIIA and 490 stage IIIB/IV) and randomized to receive 18 monthly and two quarterly intradermal injections of belagenpumatucel-L or placebo until disease progression or withdrawal. The two arms were balanced for age, disease stage and type; 57% of the patients had adenocarcinoma, 27% squamous carcinoma, and 6% large cell carcinoma. The primary end-point was OS. Recently, at the European Cancer Congress 2013 Presidential Session I, G. Giaccone presented the data of this study which did not meet its primary endpoint with a median OS of 20.7 months for the belagenpumatucel-L arm compared to 13.4 months in the control arm (HR 0.75; P=0.083). Patients treated in the belagenpumatucel-L arm within 12 weeks of chemotherapy completion, showed a non-significant improvement in median OS compared to those treated with placebo (20.7 vs 13.4months,HR 0.75; P=0.083). A relevant and statistically significant improvement in OS was observed in stage IIIB/IV non-adenocarcinoma patients (n=99) who started belagenpumatucel-L within 12 weeks of the completion of frontline chemotherapy (9.9m vs. 12.3m HR 0.55, p=0.036). Moreover, radiotherapy pretreated patients, treated with the investigational vaccine within 12 weeks of chemotherapy completion, showed an advantage of 29.8 months in OS (40.1 vs. 10.3months, HR 0.45, p=0.014). Belagenpumatucel-L showed a good safety profile in the study with only one serious adverse event (grade 2 allergic rash). Although the study did not meet its primary endpoint, it cannot be considered negative at all, because the analysis carried out by the investigators identified subgroups of patients who achieved a benefit in terms of OS. [31] These data, together with a good safety profile, support the development and the future approval of Belagenpumatucel-L with the appropriate patient selection.

### **6.1.2: GVAX**

GVAX is a gene therapy vaccine that stimulates natural defenses against tumor cells. The vaccine employ *ex vivo* transfection of autologous or allogenic tumor cells with the granulocyte-macrophage colony-stimulating factor (GM-CSF) gene, followed by lethal irradiation before inoculation to the patient. Secretion of GM-CSF by genetically modified tumor cells stimulates cytokine release at the vaccine site to

activate APCs, which prime CD4+ and CD8+ T cells to recognize circulating TAAs, thereby inducing a tumor-specific cellular immune response [32] It has been studied for various malignancies such as prostate cancer, melanoma, kidney cancer, and NSCLC. Data on the use of this vaccine in prostate cancer are not promising and the negative results, together with a high toxicity, shown in two phase III clinical trials limited further applications for this type of cancer. [33, 34] Despite these non-promising data, GVAX has been evaluated also in NSCLC patients. A first phase I study, in which 34 patients with stage IIB-IV NSCLC were treated with an autologous vaccine showed disease stabilization in five patients, one mixed response and in two patients who undergone surgery there was no evidence of disease at 43 and 42 months post-operatively. [35] Subsequently, a second phase I/II trial by Nemunaitis et al. has been conducted with GVAX produced with autologous NSCLC cells. 83 patients, 20 with early-stage NSCLC and 63 with advanced stage NSCLC were enrolled; however, vaccine was successfully created and administered to only 43 patients (33 with advanced stage and 10 with early stage). The most frequent toxic event was skin reaction in the site of injection. Three of the 33 patients with advanced disease had a complete and durable tumor response, and two of them maintained this response for more than five years. [36] These data, although arising from limited experiences on small number of patients, have been considered promising. Nevertheless, the negative studies previously conducted on prostate cancer, inhibited the research and the development of other studies using GVAX.

## **6.2 Peptide and Protein Vaccines**

### **6.2.1 MAGE-A3/vaccine**

Melanoma-associated antigen-A3 (MAGE-A3) is a TAA which represents a promising future target for cancer immunotherapy because it is not normally expressed in normal human cells except in male germline cells in which this antigen is not normally presented for the lack of MHC class I molecules. [37] MAGE-A3 expression has been demonstrated in almost 35% of NSCLCs with a trend of increase from early (30%) to late stages (55%). [38] Moreover, although its biological role is not clear, a greater expression of MAGE-A3 in advanced NSCLC patients also correlates with a worse prognosis. [39] MAGE-A3 vaccine is composed of a recombinant protein obtained by the fusion of MAGE-A3 antigen and part of the protein D of

Haemophilus influenzae, packaged with lipid adjuvants. This vaccine has been evaluated by Vansteenkiste J. et al. in a multi-center, double-blind, randomized, placebo-controlled phase II trial, in which 182 MAGE-A3+ patients, with stage I and II NSCLC, were randomized to receive MAGE-A3 protein plus adjuvant or placebo after complete surgical resection. Patients were treated with an induction of five doses administered every three weeks, and then with eight doses every three months as maintenance therapy. After a 28 months follow-up, for patients in the experimental arm, there was a non-significant but clinically relevant improvement in the disease-free interval, disease-free survival (DFS), and OS with hazard ratios (HRs) of 0.75 (95% CI: 0.46–1.23; p = 0.254), 0.76 (95% CI: 0.48–1.21; p = 0.248) and 0.81 (95% CI: 0.47–1.40; p = 0.454), respectively. Treatment showed a good tolerability profile that ensured a valid compliance of the patients in the study. [40] Despite the small number of patients in the study and the limited results showed, based on this data, a phase III study (MAGRIT trial) was initiated in 2007. This double-blinded, placebo-controlled study recruited 2278 MAGE-A3-positive stage IB, II and IIIA NSCLC patients who were randomized to receive either MAGE-A3 vaccine as adjuvant therapy or placebo after complete surgical resection. [41] Experimental treatment is composed by 13 injections in a period 27 months, after the standard of care (surgery or surgery plus adjuvant chemotherapy). Primary endpoint of the trial was DFS and secondary endpoints were OS, lung-cancer-specific survival, DFS at 2-, 3-, 4- and 5-year, disease-free specific survival, anti-MAGE-A3, and anti-protein D seropositivity rate as well as adverse events occurrence. Patient accrual of the largest NSCLC clinical trial ever has been completed in 2011, but although expectations about its results with their potential therapeutic implications were eagerly awaited, through a recent press release, GSK announced its decision to stop the trial because it didn't meet its first and co-primary endpoints. Final results and publications are still not available.

### **6.2.2 MUC1 and L-BLP25 (tecemotide)**

MUC1 is a protein normally produced by many epithelial cells and expressed on their apical surfaces and it's overexpressed in an hyper-glycosylated form by various cancer cells. [42] This type of tumor-associated MUC1 is immunologically distinct from the one produced by normal cells and its typical hyperglycosylation exposes the antigenic core of the protein to the action of the immune-competent elements.

[43] It seems to be involved in tumor cell migration and resistance to chemotherapy-related apoptosis and partially responsible of an immune system suppression through a CTL inhibition. Moreover, high levels of this protein has been found related to poor prognosis in cancer patients. [44] On the other hand, a higher level of MUC1 natural antibodies has been found to be related with a better prognosis in NSCLC patients [45] such as in pancreatic adenocarcinoma [46] and in patients with early stage breast cancer [47] L-BLP25 (tecemotide) is a peptide vaccine composed of the immunogenic portion of MUC1 protein-linked to a lipodic adjuvant (monophosphoryl lipid A), and three lipids (cholesterol, dimyristoyl phosphatidylglycerol, and dipalmitoyl phosphatidylcholine).[48] This vaccine targets the core of MUC-1 when hyperglycosylated and elicits an immune response with the subsequent production of IFN- $\gamma$  and tumor-specific CTL proliferation. This promising drug has been evaluated in 2007 by Butts et al., in a phase IIB trial in which 171 stage IIB/IV NSCLC patients were randomized to receive BSC plus L-BLP25 (n = 88) or BSC alone (n = 83) after response or stable disease to first-line chemotherapy. [49] Patients in the L-BLP25 arm received a single intravenous dose of cyclophosphamide 300 mg/m<sup>2</sup> before the vaccine, followed by eight weekly administrations of the vaccine (1,000 mcg). Subsequent maintenance administrations could be given with 6-week intervals until disease progression. The primary end-point of the study was median OS which resulted 17.4 months for L-BLP25 patients versus 13.0 months for the control arm (adjusted HR: 0.739; 95% CI: 0.509–1.073; p = 0.112). Despite the lack of statistical significance of this advantage, a subgroup analysis of the 35 stage IIB patients with loco-regional disease and treated with L-BLP25 plus BSC, showed a 17.3 months difference in median OS (30.6 months vs. 13.3 months, HR = 0.524; 95% CI 0.261–1.052; P = 0.069) over the BSC group. The safety profile was good with only few adverse events like mild flu-like symptoms and injection site reactions. [50] Although these results were limited and non-statistically significant, the START trial, a multi-center phase III randomized, double-blind placebo-controlled study was initiated in 2007. In this large trial, 1239 patients with stage IIIA/B unresectable NSCLC without progression following chemoradiotherapy were randomized to receive weekly administrations of L-BLP25 (Tecemotide) 806  $\mu$ g for 8 weeks then every 6 weeks thereafter plus BSC or placebo plus BSC; both arms continued until progression. Although there was trend toward improved OS (the primary endpoint of the trial) with the vaccine, difference from placebo did not reach statistical significance; OS was 25.6 months in the L-BLP25 arm vs 22.3 months in the placebo group (adjusted HR 0.88, 95% CI: 0.75-1.03, P=0.123). The subgroup analysis of

patients who received previous concurrent chemoradiotherapy (n=538) showed a significant benefit of 10.2 months in OS with tecemotide (HR: 0.78; P = .016). This advantage was absent in the group of those who received tecemotide after sequential chemoradiotherapy (HR 1.11; P = .38). Tecemotide has once again been demonstrated to be a very well tolerated treatment and a possible valuable weapon for some patients in maintenance therapy after chemoradiotherapy. [51] Based on these data, another phase III study of tecemotide has just been initiated, the START-2 trial: a randomized study for patients with unresectable stage III NSCLC who had either stable disease or objective response following primary concurrent chemoradiotherapy treated with L-BLP25 or placebo. [52] The INSPIRE trial is another similar phase III trial with tecemotide for Asian patients with stage III unresectable NSCLC, and it is still recruiting patients. [53]

### **6.2.3 EGF Vaccine: CIMAVax**

EGFR and its ligand EGF are considered key elements in many malignancies. Targeting EGFR pathway when mutated with TKIs, it is today a very well known treatment modality in NSCLC. [54] Moreover, EGFR is over-expressed in a very high proportion of NSCLCs. [55] CIMAVax vaccine is composed by human recombinant epidermal growth factor linked to a carrier protein, P64K from *Neisseria meningitidis*, and administered with an adjuvant. The use of this vaccine induces the production of anti-EGF antibodies whose activity reduces the activation of EGFR, and hence, inhibits tumor cells' proliferation. [56] In a phase II study, 80 patients with stage IIIB or IV NSCLC previously treated with first-line chemotherapy were enrolled. In this small trial performed by Neningen et al., patients were randomized to receive either vaccination plus BSC or BSC alone. The investigational vaccine was administered on days 1, 7, 14, 28 and monthly thereafter, after a priming dose of cyclophosphamide (200 mg/m<sup>2</sup>) was administered. [57] The measurement of EGF in patients' serum showed reduced EGF concentrations in those in the experimental arm which indirectly confirmed that CIMAVax caused the production of anti-EGF antibodies. Because of the small number of patients enrolled, the results of the study showed a non-statistically significant survival benefit for patients treated with the vaccine (6.5 months vs 5.3 months; P = 0.098) but the improvement in median OS reached significance in the subgroup of patients younger than 60 years (11.5 months vs 5.3 months p = 0.0124). In addition, a statistically significant

improvement in survival (11.7 months versus 3.6 months;  $P = 0.002$ ) was also seen for patients with EGF antibody titers  $\geq 1:4000$ . No critical side effects occurred in this trial. [57] A larger phase II/III (Malaysian trial) study started but interrupted in 2011 due to poor enrollment. [58]

### **6.3 Viral vector vaccines: TG4010**

TG4010 is an anti-cancer vaccine composed by an attenuated Ankara virus, genetically modified to express MUC1 antigen and IL-2. [59] The latter has been introduced to bypass the MUC1 related T-cell suppression. [44] This vaccine has been studied in a phase II trial in which 65 patients with stage IIIB/IV NSCLC were randomized to receive either TG4010 in addition to cisplatin-vinorelbine chemotherapy or the vaccine alone (continued until progression). [60] Those patients who progressed in the control arm were treated with a cross-over to the experimental arm, with the same chemotherapy. The median OS was 12.7 months for the chemotherapy plus vaccine arm (arm1) and 14.9 for the vaccine only arm (arm2). One year survival rate was 53% for Arm 1 and 60% for Arm 2; in the latter, two patients experienced stable disease for more than 6 months. A subsequent phase IIb trial evaluated this vaccine in a larger number of patients, in combination with cisplatin and gemcitabine. In this trial, 148 untreated patients diagnosed with stage IIIB or IV MUC1-positive NSCLC were randomized to receive cisplatin and gemcitabine, with or without TG4010. In the experimental arm, the vaccine was administered with subcutaneous injections each week for 6 weeks and then every 3 weeks until disease progression. Primary endpoint was 6-month PFS, with a target rate of 40% or higher in the experimental group. The results of the trial showed that the addition of TG4010 to chemotherapy confers a clinically relevant advantage in terms of PFS to the patients. In fact, PFS rate at 6 months was 43% (95% CI: 33–54) in the experimental arm and 35% (95% CI: 26–45) in the chemotherapy alone arm ( $P = 0.13$ ) while no difference in OS was demonstrated. Overall response rates (ORR) were 43% in patients receiving the vaccine vs. 27% in patients receiving chemotherapy only. In addition, the subgroup analysis of patients in the chemotherapy plus TG4010 group (with normal levels of activated NK cells) showed an improvement in response rate and OS (58% vs. 38%,  $P = 0.04$  and 18 months vs. 11.3 months,  $P = 0.02$ , respectively). [61] Based on these data, a phase IIb/III randomized, double-blind, placebo-controlled trial started to evaluate this effect in a larger population, and trying to answer the question if the addition of TG4010 to standard first-line chemotherapy confers an advantage to MUC1-positive stage IV

NSCLC patients. Primary endpoint is OS and the investigators will try to prospectively validate activated NK level as a predictive biomarker with PFS as a primary endpoint, by comparing the two treatment arms in two subgroups defined according to the level of aNK cells at baseline (normal or high). [62] This trial is still active and recruiting patients. [63]

#### **6.4 Ganglioside vaccines: Racotumomab**

Gangliosides are a family of glycosphingolipids present on the surface of cells' membrane which are involved in cell communication, cell matrix adhesion, cell differentiation, and regulation of the immune response and are expressed on the surface of tumor cells. [64] N-glycolylneuraminic acid (NeuGc) is a sialic acid which has been found, conjugated with GM3 ganglioside (NeuGcGM3) expressed by NSCLC cells and considered as a possible target for immunotherapy. [65] Racotumomab (1E10), is an anti-NeuGc-containing gangliosides anti-idiotypic monoclonal antibody (mAb). Preclinical data suggest a promising activity of this vaccine [66] also in combination with chemotherapy. [67] In a compassionate study published in 2007 by Alfonso et al., 34 patients with stage IIIB and 37 stage IV NSCLC patients were treated with the anti-idiotypic vaccine, after received standard chemotherapy and radiotherapy. Patients received five biweekly administration of the vaccine followed by monthly maintenance administration. The OS was 9.93 months (95% CI, 8.61-11.25) with a 1-year survival rate of 34%. Those patients who had ECOG performance status 1 (PS1) and started the experimental treatment after a PR or stabilization due to first line treatments, had a more consistent benefit in OS (11.50 months, 95% CI 7.97-15.03) and a 1-year survival of 39%. Toxicity profile was good and the most common side-effects were local reaction at the injection site and fever. [68] Currently, a prospective, randomized, open label, parallel-group, multicenter phase III study is still recruiting patients. This study will evaluate racotumomab for NSCLC patients with advanced disease who have achieved an objective response or stable disease with standard first-line treatment. [69] At the 2013 ASCO annual meeting, Gomez et al. presented the data of an open, non-randomized study to evaluate if racotumomab could give a benefit to patients with NSCLC in progression. A total of 180 patients were included, and after at least 10 months of follow-up median survival was 8.06 months and OS rate at 24 months was 21%. A control group of 85 patients who did not receive second-line therapy or

racotumomab showed a median survival of 6.26 months ( $p= 0.011$ ) and OS rate at 24 months was only 7%.

## **7. Immunomodulators and NSCLC**

As previously explained, a possible strategy to stimulate an immune response against cancer is to modulate the functions of the principal actors of the immune system. Obviously, the introduction of cancer-specific antigens leads the immune-system to react against precise targets while immunomodulation causes the enhancement of the existing mechanisms with a wider spectrum of consequences including the aggression of cancer cells but also autoimmunity events. The enhancement of the immune system can be obtained either with the introduction of immune-stimulating factors such as DCs, injection of CTLs or activated NK cells, IL-2 or IFN- $\alpha$  or by the inhibition of the immune-inhibiting elements which are responsible of the tolerance to cancer (e.g., inhibition of T-reg cells and blocking inhibiting cytokines). [27] Historically but not clinically relevant are the first attempts of using immunomodulators for lung cancer such as the administration of BCG [70] or mycobacterium-derived vaccine (SRL172) [71] alone or in association with chemotherapy. Negative data emerged also from clinical trials with PF-3512676, a synthetic TLR9-activating oligodeoxynucleotide, which works as the natural ligand of TLR9 which enhances maturation of DCs. [72, 73] Also, lactoferrin which is an iron-binding glycoprotein found in breast milk has shown several immunomodulatory functions. [74] Talactoferrin alpha is the recombinant human variant of lactoferrin, purified from *Aspergillus niger* var *awamori* and administered orally and transported into the gut-associated lymphoid tissue where it induces DC maturation. [75] Based on positive data from phase 2 trials [76, 77], two phase 3 studies tried to evaluate the activity of talactoferrin alpha in patients with NSCLC. In the first one, the FORTIS-M trial, talactoferrin alpha was administered to patients with refractory advanced NSCLC in comparison with placebo and the results showed no improvement in efficacy with this drug [78]. The second trial (FORTIS-C trial) studied talactoferrin alpha in association with chemotherapy as a first-line treatment in advanced or metastatic NSCLC. However, due to negative results of the FORTIS-M trial, Agennix AG decided to stop enrollment and analyze the results.

A promising immunotherapy approach for NSCLC is the blockade of inhibitory 'checkpoint pathways' and the following paragraphs focus on the possible therapeutic targets and on the clinical implications of this type of approach.

### **7.1 CTLA-4 inhibitor: Ipilimumab in Lung Cancer**

CTLA-4 is an immunomodulatory receptor expressed by activated CD4+ and CD8+ T-lymphocytes that works as a negative regulator of T-cell-mediated immune response. Ipilimumab is a fully human IgG1 mAb directed against CTLA-4 whose activity prevents the interaction between CTLA-4 and its ligands (CD80/CD86), thus, producing a blockade of the inhibitory signal provided by CTLA-4, and enhancing the activation and proliferation of tumor-specific T-cells. [79, 80] Based on the results of two randomized phase 3 trial that showed an improvement in OS for ipilimumab compared with vaccine alone or standard dacarbazine chemotherapy, this mAb has been approved for treatment of metastatic melanoma, representing a real turning point for patients with a such aggressive type of cancer. [81, 82] Ipilimumab has been evaluated in a phase II trial for advanced NSCLC and SCLC patients who were randomized to receive as first line therapy paclitaxel plus carboplatin with either placebo or ipilimumab administered with a concurrent (four doses of ipilimumab plus paclitaxel and carboplatin followed by two doses of placebo plus paclitaxel and carboplatin) or with a phased regimen (two doses of placebo plus paclitaxel and carboplatin followed by four doses of ipilimumab plus paclitaxel and carboplatin). Treatment was administered intravenously every 3 weeks and not over 18 weeks (induction). Patients with no progression continued ipilimumab or placebo every 12 weeks as maintenance therapy until progression, death, or intolerance. Results for NSCLC and SCLC were published separately. The trial met its primary endpoint, immune-related progression-free survival (irPFS), for NSCLC patients (N = 204) but only for those treated with phased ipilimumab (5.7 vs 4.6 months, HR=0.72; P = 0.05) while in the concurrent ipilimumab group, no significant improvement was demonstrated (5.5 vs 4.6 months; HR=0.81; P = 0.13). In the three groups of patients, phased, concurrent ipilimumab and control, median OS was 12.2, 9.7 and 8.3 months, respectively. Two patients died from treatment-related toxicity and severe adverse events seem to be more frequent in the concurrent group. In the phased ipilimumab group, patients with squamous cell carcinomas had a more significant improvement in irPFS (HR: 0.55) than patients with adenocarcinoma (HR:

0.82) and similar results were found in the concurrent arm. [83] Data for patients with advanced SCLC showed that phased ipilimumab, but not concurrent ipilimumab, improved irPFS versus control (HR=0.64; P=0.03) while no improvement in PFS (HR=0.93; P=0.37) or OS (HR=0.75; P=0.13) was obtained. In the phased, concurrent and control arms median irPFS was 6.4, 5.7 and 5.3 months, and a median OS of 12.9, 9.1 and 9.9 months, respectively. Overall rates of grade 3-4 adverse events were 17, 21 and 9% for phased ipilimumab, concurrent ipilimumab and control, respectively. [84] These promising data led to open two phase III trial started to evaluate ipilimumab immunotherapy for lung cancer. The first study (NCT01285609), presented at the 2013 ASCO meeting, is a randomized, multicenter, double-blind, phase 3 study comparing ipilimumab in combination with paclitaxel and carboplatin versus placebo in addition to paclitaxel and carboplatin for stage IV/recurrent NSCLC patients with squamous histology with OS as primary endpoint. [85] The second study (NCT01450761) presented at the same congress, will evaluate the efficacy of the addition of Ipilimumab to etoposide and platinum chemotherapy, for patients with extensive-stage disease SCLC in comparison with etoposide and platinum therapy alone. [86] These two trials are still recruiting patients and obviously the expectations are great about the possible clinical implications of their results.

## **7.2 Anti-PD-1 Antibodies**

Programmed cell death protein 1 (PD-1) belongs to the B7-CD28 superfamily, and works as a receptor which can be expressed on T-lymphocytes, B cells, NK cells, activated monocytes and DCs. It normally binds two ligands: PD-L1 (B7-H1) and PD-L2 (B7-DC). [87] The interaction between PD-1 and its ligands results in a diminished T-cell proliferation, altered cytokine production and initiation of T-cell exhaustion and/or apoptosis. These functions explain the immunosuppressive role of PD-1 which limits the risk of autoimmune reactions but also decreases the anti-tumor activity of CD8+ lymphocytes. [88] Blockage of this immune checkpoint is considered one of the most promising field of study to enhance the immune response against cancer cells and several anti-PD-1 agents are in development: two of them are nivolumab and lambrolizumab (MK-3475). Nivolumab (BMS-936558 formerly MDX-1106/ONO-4538) is a fully human IgG4 mAb directed against the PD-1 receptor which showed a promising spectrum of activity in a phase I trial in 296

patients with refractory solid tumors including 129 patients with NSCLC. [89] Patients were treated with five escalation doses from 0.1 mg/kg to 10.0 mg/kg every 2 weeks for up to 12 8-week cycles. As showed recently, the 129 pretreated NSCLC patients (non-squamous n=74, squamous n=54, unknown histology n=1) received nivolumab 1, 3, and 10 mg/kg IV every 2 weeks and 22 patients (17%) had responses (CR/PR) with a median duration of 74 weeks (range 6.1+ to 133.9+ weeks). The highest ORR was at 3 mg/kg (24%) across the various histologies. Median OS across all doses was 9.6 months and 14.9 months at 3 mg/kg across all histologies. Median OS across all doses was similar for squamous (9.2 months) and non-squamous patients (10.1 months) while at the 3 mg/kg dose, a difference in median OS (9.5 months for squamous NSCLC; 18.2 months for non-squamous) was reported. Moreover, the one-year survival rate was 43% for non-squamous NSCLC patients and 39% for squamous NSCLC patients across all doses. About toxicity of nivolumab any grade adverse events was seen in 53/129 patients (41%) while grade 3/4 events occurred only in 6/129 patients (5%). [90] Data of activity and tolerability of nivolumab in strongly pretreated NSCLC patients, led to the start of two phase III trials which are evaluating nivolumab as second line monotherapy vs docetaxel both in squamous (NCT01642004, OS and ORR as primary endpoint) [91] and non-squamous (NCT01673867, OS primary endpoint) NSCLC. [92] These studies are still ongoing. Another phase I trial is testing nivolumab in combination with three platinum-based doublet chemotherapy regimens (Cisplatin/Gemcitabine; Cisplatin/Pemetrexed; and Carboplatin/Paclitaxel), with targeted drugs (Bevacizumab and erlotinib), with ipilimumab, in monotherapy and in maintenance in patients with advanced NSCLC. [93] Nivolumab is being evaluated also as third line therapy in a phase II trial with ORR as primary endpoint in patients with advanced or metastatic squamous NSCLC after failure of two prior systemic therapies. [94] Another phase II trial is also evaluating the epigenetic priming with azacitidine and entinostat or oral azacitidine alone prior to nivolumab in recurrent metastatic NSCLC patients. [95] Lambrolizumab (MK-3475) is another anti PD-1 humanized IgG4 monoclonal antibody which has been defined by FDA as "breakthrough therapy" for the durable results obtained in the treatment of patients with advanced melanoma. [96] Preliminary data of MK-3475 in pretreated NSCLC patients have been presented at the 15<sup>th</sup> World Conference on Lung Cancer in Sidney, Australia. In this study, lambrolizumab was administered at the dose of 10 mg/kg every 3 weeks in 38 treatment - refractory patients with NSCLC: ORR was 24% and most of the responses were observed by the time of first planned assessment at

week 9. [97] The drug is being studied in comparison with both docetaxel in NSCLC patients after failure of a platinum-based regimen [98] and with chemotherapy or immunotherapy. [99]

### **7.3 Anti-PD-L1 Antibodies**

Another way to block PD1- immune checkpoint is to reduce the activity of its ligand and for this reason mAbs directed against PD-L1 are in development. PD-L1 is a transmembrane protein expressed by various elements of the immune system and its expression in solid tumors seems to be associated with tumor grade, squamous histology, immune cell density, and co-localization of PD-L1+ immune cells [100]. Data from preliminary studies suggest that the expression of PD-L1 on human cancers evaluated with immunohistochemistry in formalin-fixed paraffin embedded tissue samples (FFPE) could be a prediction test for response to anti PD-1/PD-L1 therapy. [101, 102] In a recent study by Velcheti et al., antibodies and *in situ* mRNA hybridization were used to evaluate PD-L1 expression in NSCLC using quantitative fluorescence (QIF) to determine the frequency of expression and prognostic value in two cohorts of patients from Greece (N=340) and USA (N=204). PD-L1 expression was 36% in Greek and 25% in USA patients and it was related with the presence of a consistent lymphocyte infiltrate in tumors. Surprisingly, patients with protein and mRNA PD-L1 expression showed statistically better outcome in both groups, independently of the histology. These data are in contrast with previous studies which reported that the expression of PD-L1 protein in various malignancies, including in NSCLC, was associated with worse outcome. [103-106] BMS-936559 (MDX-1105) is a fully human IgG4 anti-PD-L1 monoclonal antibody that blocks the binding of PD-L1 to both PD-1 and CD80. It has been evaluated in a phase I trial for patients with various types of cancers including 75 NSCLC patients. Five of the 49 assessable NSCLC patients showed response with a range of duration of 1.6 to 2.3 months. Toxicity profile was acceptable with only 9% of grade 3/4 drug-related adverse events. [102] MPDL3280A is another anti PD-L1 monoclonal antibody in development whose modified Fc domain seems to maximize the therapeutic effects minimizing the antibody dependent cellular cytotoxicity-mediated depletion of activated T –lymphocytes. This drug has been studied in a dose escalation phase I trial in which 175 patients with solid tumors have been treated. Preliminary data for the 41 evaluable NSCLC patients first dosed at 1-20 mg/kg, showed an ORR of 22%

(9/41), and responses were lasting for a range of 1+ to 214+ days. Curiously, the ORR was 23% (8/35) for former/current smokers versus 17% (1/6) for non-smokers, and it seems also to be associated with PD-L1 tumor status [107]. A phase Ib trial will assess of intravenous MPDL3280A in combination with erlotinib administered to patients with locally advanced or metastatic non-small cell lung cancer (NSCLC). [108] MPDL3280A is also being evaluated in three phase 2 trials: in two of them as monotherapy for patients with PD-L1-positive locally advanced or metastatic NSCLC [109, 110] and in the third one in comparison with docetaxel for platinum refractory patients.[111] Moreover a phase III multicenter, open-label, randomized, controlled has started to evaluate MPDL3280A in comparison with docetaxel in patients with locally advanced or metastatic NSCLC after failure with platinum-containing chemotherapy.

## **8. Expert Commentary**

It has been a long road before to see any hope that immunotherapy finally will be coming as an option for lung cancer therapy. Lung cancer tumors always had the reputation to be not very immunogenic and the fact that we have not really discover the antigen (s) that are the key to generate an adequate immune response made the things worse. We have tried over the years whole cell vaccines, we have tried several specific antigens, we have done autologous vaccinations and allogeneic ones. Finally in the last 3 years information of the first four randomized phase III clinical trials of promissory lung cancer vaccines have been arriving, unfortunately most of them are unable to prove improvements in survival but in some cases like blp-25 (former stimuvax) the final story is not written yet and we will have a second chance with the new prospective randomized trial for concurrent chemoradiation patients. The new hope arrived with the check point inhibitors that are new options for immunotherapy and after the success of antiCTLA4 in other tumors we have a lot of expectation to see if we can get this agent approved for lung cancer. Finally the discovery of PD-1/PDL-1 as potential targets in lung cancer brings another option to the table, the original data as we have review here its solid and very promissory.

Also we can not forget that in general immunotherapy has proven to be less toxic than chemotherapy giving even incurable patients a much better quality of life, so the goal is not only to try to cure this terrible disease but also to prolong survival with excellent and decent quality of life making lung cancer a chronic disease as first step towards the cure.

Then after being for many years the God that was forgotten in the garden of the lords, we hope that immunotherapy will become a major divinity.**9. Five-year view**

Perhaps, few years ago we still thought that immunotherapy will not impact lung cancer survival. Immunotherapy has had up and down in lung cancer treatment roadmap. Sometimes showing provocative and intriguing results, but without showing an improved OS in a large phase III randomized placebo-controlled trial. Nonetheless, we believe that soon this paradigm will change. The advances in bio-immunology has taught us how to target those intrinsic immune mechanism which are shut down by tumor cancer cells. Novel agents such as anti-PD1 and PD-L1 antibodies are shaking all prior experiences that we had had in the past trying to elicit immune response against cancer cells using vaccines with different kind of antigens, adjuvant (carrier) and procedures.

As we moving to the concept of “personalized” or individualize therapy, trying to minimize toxicity for the patient and attained maximum response which translate into survival advantage, maybe the effective way to improve the immune response against NSCLC will be by inhibiting suppressing factors that block the immune response. These novel agents such as nivolumab, lambrilozumab, MPDL3280A, and others are reporting good responses in advanced NSCLC. Due to their toxicity profile, it seems that we can combine them with chemotherapy and perhaps, move them into early stages. This is a new field, and we have to wait for ongoing clinical trials to mature and report their results. One of the many questions that needs to be answered in the next 5-year is what mechanism is more effective to block PD1 or its ligand to exert maximum response. Also, are they effective in the adjuvant setting? Or is this an area in which vaccination will still may have an impact? Meanwhile, the efficacy and reported data from these immunomodulators are encouraging and opening many hypothesis and clinical use, that we as clinicians should be tuned for all development to come in the next few years.

In the other hand, well advanced clinical trials already completed or ready to start using vaccines are eagerly waited, such as MAGRIT and START2 trials. At the end of this journey, we sense that we are close to finally reach an immunotherapy approach that can help us to improve OS and cure rate in lung cancer.

## **10. Conclusions**

Recently, a better understanding of the biology of immune system in lung cancer, led to the development of several immunotherapeutic agents, resulting in two major proposed therapeutic strategies: antigen-specific immunotherapy or cancer vaccination, and non-antigen-specific immunotherapy or cancer immunomodulation. Vaccine therapy has not proven effective to date, but both activity and very low toxicity profile define a unique treatment opportunity. Immunomodulators, working as checkpoint inhibitors in the interaction between T-cells and cancer cells, have shown impressive activity in early clinical trials, representing the best pathway to target for the achievement of an immunological response against cancer cells. Waiting for the confirmatory results from ongoing randomized phase III trials, some issues still need to be solved. We need to develop more accurate predictive biomarkers for patients selection, in order to treat subgroup of patients who could benefit more and have their disease controlled for a long period of time. Indeed, most of the patients who are benefiting from immunotherapy are disease progression free after a long time of treatment, suggesting that their immune system has been reset in a way that could allow them to live with their disease. Furthermore, the immune response may take longer time to become clinically evident, compared with standard cytotoxic therapy, sometimes leading to a temporary increase of the tumor target lesions, because of the inflammatory infiltrate, subsequently followed by the final tumor shrinking. Therefore we need to validate specific immune-response criteria for the assessment of immunotherapy activity, because the commonly used RECIST criteria, might not be appropriate to evaluate the activity of the new immune drugs. Even if most of the trials so far have used immunomodulators alone in metastatic lung cancer, we also need to work out when is preferable to use immunotherapy in the course of lung cancer, moving our interest on early disease. Ongoing trials are exploring the use of these agents in combination with other therapies, such as chemotherapy, radiotherapy, and targeted agents, suggesting that combination treatments could increase the activity of immunotherapy for NSCLC. Finally combining the different immunotherapeutic agents could also produce a synergistic effect. If these findings would be confirmed, immunotherapy will most likely become part of daily practice for NSCLC in the near future, conferring the opportunity to finally enter in the pantheon of lung cancer treatments.

### **Key issues**

- Survival outcomes of advanced NSCLC patients are still poor for the majority of them but the introduction of targeted therapies represented a critical turning point for the treatment of molecular selected patients.
- The immune system is widely involved in the complex mechanisms of development, growth and spreading of malignant tumors, including NSCLC.
- Although lung cancer has been considered non-immunogenic for years, some scientific evidences suggest the opposite, especially for squamous NSCLC;
- Two ways can be used to improve immune response against cancer: enhancing immune stimulating components to start or maintain an effective response, or inhibiting suppressing factors limiting the immune response.
- Many vaccines have been evaluated using different targets and others are still under evaluation. Promising data are coming especially from Belagenpumatucel-L, a whole cell vaccine, MAGE-A3 vaccines and tecemotide, an anti- MUC1 vaccine;
- The inhibition of immune-checkpoints is a possible strategy to enhance immune response against cancer.
- Ipilimumab showed promising activity in phase II trials for patients with advanced squamous NSCLC and SCLC improving both PFS and OS.
- Anti PD-1 antibodies, nivolumab and lambrolizumab, works through the inhibition of the interaction of PD-1 and its ligands. Preliminary promising data encouraged the start of larger studies.
- Anti PD-L1 antibodies BMS-936559 (MDX-1105) and MPDL3280A showed promising results and they are currently being evaluated both in monotherapy and in combination with other anticancer agents.

## References

1. Ferlay, J., et al., *Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008*. Int J Cancer, 2010. **127**(12): p. 2893-917.
2. Molina, J.R., et al., *Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship*. Mayo Clin Proc, 2008. **83**(5): p. 584-94.
3. Ma, P.C., *Personalized targeted therapy in advanced non-small cell lung cancer*. Cleve Clin J Med, 2012. **79 Electronic Suppl 1**: p. eS56-60.
4. Robert, C., et al., *Efficacy and safety of retreatment with ipilimumab in patients with pretreated advanced melanoma who progressed after initially achieving disease control*. Clin Cancer Res, 2013. **19**(8): p. 2232-9.

5. Kantoff, P.W., et al., *Sipuleucel-T immunotherapy for castration-resistant prostate cancer*. N Engl J Med, 2010. **363**(5): p. 411-22.
6. Dunn, G.P., L.J. Old, and R.D. Schreiber, *The three Es of cancer immunoediting*. Annu Rev Immunol, 2004. **22**: p. 329-60.
7. O'Sullivan, T., et al., *Cancer immunoediting by the innate immune system in the absence of adaptive immunity*. J Exp Med, 2012. **209**(10): p. 1869-82.
8. Finn, O.J., *Cancer immunology*. N Engl J Med, 2008. **358**(25): p. 2704-15.
9. Swann, J.B. and M.J. Smyth, *Immune surveillance of tumors*. J Clin Invest, 2007. **117**(5): p. 1137-46.
10. Marincola, F.M., et al., *Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance*. Adv Immunol, 2000. **74**: p. 181-273.
11. Lee, J.C., et al., *Elevated TGF-beta1 secretion and down-modulation of NKG2D underlies impaired NK cytotoxicity in cancer patients*. J Immunol, 2004. **172**(12): p. 7335-40.
12. Gancz, D. and Z. Fishelson, *Cancer resistance to complement-dependent cytotoxicity (CDC): Problem-oriented research and development*. Mol Immunol, 2009. **46**(14): p. 2794-800.
13. Igney, F.H. and P.H. Krammer, *Immune escape of tumors: apoptosis resistance and tumor counterattack*. J Leukoc Biol, 2002. **71**(6): p. 907-20.
14. Nagata, S., *Fas ligand and immune evasion*. Nat Med, 1996. **2**(12): p. 1306-7.
15. Schimmer, A.D., *Inhibitor of apoptosis proteins: translating basic knowledge into clinical practice*. Cancer Res, 2004. **64**(20): p. 7183-90.
16. Brichard, V.G. and D. Lejeune, *Cancer immunotherapy targeting tumour-specific antigens: towards a new therapy for minimal residual disease*. Expert Opin Biol Ther, 2008. **8**(7): p. 951-68.
17. Dy, G.K. and A.A. Adjei, *Emerging therapeutic targets in non-small cell lung cancer*. Proc Am Thorac Soc, 2009. **6**(2): p. 218-23.
18. Dieu-Nosjean, M.C., et al., *Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures*. J Clin Oncol, 2008. **26**(27): p. 4410-7.
19. Hiraoka, K., et al., *Concurrent infiltration by CD8+ T cells and CD4+ T cells is a favourable prognostic factor in non-small-cell lung carcinoma*. Br J Cancer, 2006. **94**(2): p. 275-80.
20. Petersen, R.P., et al., *Tumor infiltrating Foxp3+ regulatory T-cells are associated with recurrence in pathologic stage I NSCLC patients*. Cancer, 2006. **107**(12): p. 2866-72.
21. Grunwald, C., et al., *Expression of multiple epigenetically regulated cancer/germline genes in nonsmall cell lung cancer*. Int J Cancer, 2006. **118**(10): p. 2522-8.

22. Echchakir, H., et al., *A point mutation in the alpha-actinin-4 gene generates an antigenic peptide recognized by autologous cytolytic T lymphocytes on a human lung carcinoma*. *Cancer Res*, 2001. **61**(10): p. 4078-83.
23. Takenoyama, M., et al., *A point mutation in the NFYC gene generates an antigenic peptide recognized by autologous cytolytic T lymphocytes on a human squamous cell lung carcinoma*. *Int J Cancer*, 2006. **118**(8): p. 1992-7.
24. Rekhtman, N., et al., *Immunohistochemical algorithm for differentiation of lung adenocarcinoma and squamous cell carcinoma based on large series of whole-tissue sections with validation in small specimens*. *Mod Pathol*, 2011. **24**(10): p. 1348-59.
25. Bolli, M., et al., *Tissue microarray evaluation of Melanoma antigen E (MAGE) tumor-associated antigen expression: potential indications for specific immunotherapy and prognostic relevance in squamous cell lung carcinoma*. *Ann Surg*, 2002. **236**(6): p. 785-93; discussion 793.
26. J.-H. Kim, J.I.Z., H. Nakayama, T. De Pas, et al. , *Patient and tumor characteristics impacting on MAGE-A3 expression: screening data from the MAGRIT Phase III trial, 2011 World Congress of Lung Cancer; July 3–7, 2011; Amsterdam, Netherlands. Session MO21*.
27. Zou, W., *Immunosuppressive networks in the tumour environment and their therapeutic relevance*. *Nat Rev Cancer*, 2005. **5**(4): p. 263-74.
28. Decoster, L., I. Wauters, and J.F. Vansteenkiste, *Vaccination therapy for non-small-cell lung cancer: review of agents in phase III development*. *Ann Oncol*, 2012. **23**(6): p. 1387-93.
29. Nemunaitis, J., et al., *Phase II study of belagenpumatucel-L, a transforming growth factor beta-2 antisense gene-modified allogeneic tumor cell vaccine in non-small-cell lung cancer*. *J Clin Oncol*, 2006. **24**(29): p. 4721-30.
30. Fakhrai, H., et al., *Correlation of immune responses and survival in a phase II study of belagenpumatucel-L in non-small cell lung cancer*. *ASCO Meeting Abstracts*, 2009. **27**(15S): p. 3013.
31. Giaccone G, B.L., Nemunaitis J, et al, *A phase III study of belagenpumatucel-L therapeutic tumor cell vaccine for non-small cell lung cancer. 2013 European Cancer Congress. Abstract LBA 2. Presented September 28, 2013*.
32. Eager, R. and J. Nemunaitis, *GM-CSF gene-transduced tumor vaccines*. *Mol Ther*, 2005. **12**(1): p. 18-27.
33. Higano C, S.F., Somer B, et al., *A phase III trial of GVAX immunotherapy for prostate cancer vs docetaxel plus prednisone in asymptomatic, castration-resistant prostate cancer (CRPC)*. *Proc Am Soc Clin Oncol (2009 Genitourinary Cancer Symposium)*; Abstract # LBA150.
34. Small E, D.T., Gerritsen WR, et al., *A phase III trial of GVAX immunotherapy for prostate cancer in combination with docetaxel versus docetaxel plus*

- prednisone in symptomatic, castration-resistant prostate cancer (CRPC).* Presented at the Genitourinary Cancers Symposium 2009;83:abstr 07.
35. Salgia, R., et al., *Vaccination With Irradiated Autologous Tumor Cells Engineered to Secrete Granulocyte-Macrophage Colony-Stimulating Factor Augments Antitumor Immunity in Some Patients With Metastatic Non-Small-Cell Lung Carcinoma.* Journal of Clinical Oncology, 2003. **21**(4): p. 624-630.
  36. Nemunaitis, J., et al., *Granulocyte-macrophage colony-stimulating factor gene-modified autologous tumor vaccines in non-small-cell lung cancer.* J Natl Cancer Inst, 2004. **96**(4): p. 326-31.
  37. Takahashi, K., et al., *Identification of MAGE-1 and MAGE-4 proteins in spermatogonia and primary spermatocytes of testis.* Cancer Res, 1995. **55**(16): p. 3478-82.
  38. Sieneel, W., et al., *Melanoma associated antigen (MAGE)-A3 expression in Stages I and II non-small cell lung cancer: results of a multi-center study.* Eur J Cardiothorac Surg, 2004. **25**(1): p. 131-4.
  39. Gure, A.O., et al., *Cancer-testis genes are coordinately expressed and are markers of poor outcome in non-small cell lung cancer.* Clin Cancer Res, 2005. **11**(22): p. 8055-62.
  40. Vansteenkiste, J., et al., *Adjuvant MAGE-A3 immunotherapy in resected non-small-cell lung cancer: phase II randomized study results.* J Clin Oncol, 2013. **31**(19): p. 2396-403.
  41. GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patient With Non-Small Cell Lung Cancer <http://clinicaltrials.gov/ct2/show/NCT00480025>.
  42. Vlad, A.M., et al., *MUC1 immunobiology: from discovery to clinical applications.* Adv Immunol, 2004. **82**: p. 249-93.
  43. Ho, S.B., et al., *Heterogeneity of mucin gene expression in normal and neoplastic tissues.* Cancer Res, 1993. **53**(3): p. 641-51.
  44. Agrawal, B., et al., *Cancer-associated MUC1 mucin inhibits human T-cell proliferation, which is reversible by IL-2.* Nat Med, 1998. **4**(1): p. 43-9.
  45. Hirasawa, Y., et al., *Natural autoantibody to MUC1 is a prognostic indicator for non-small cell lung cancer.* Am J Respir Crit Care Med, 2000. **161**(2 Pt 1): p. 589-94.
  46. Hamanaka, Y., et al., *Circulating anti-MUC1 IgG antibodies as a favorable prognostic factor for pancreatic cancer.* Int J Cancer, 2003. **103**(1): p. 97-100.
  47. Blixt, O., et al., *Autoantibodies to aberrantly glycosylated MUC1 in early stage breast cancer are associated with a better prognosis.* Breast Cancer Res, 2011. **13**(2): p. R25.
  48. Sangha, R. and C. Butts, *L-BLP25: a peptide vaccine strategy in non small cell lung cancer.* Clin Cancer Res, 2007. **13**(15 Pt 2): p. s4652-4.

49. Butts, C., et al., *Randomized phase IIB trial of BLP25 liposome vaccine in stage IIB and IV non-small-cell lung cancer*. J Clin Oncol, 2005. **23**(27): p. 6674-81.
50. Butts, C., et al., *Updated survival analysis in patients with stage IIB or IV non-small-cell lung cancer receiving BLP25 liposome vaccine (L-BLP25): phase IIB randomized, multicenter, open-label trial*. J Cancer Res Clin Oncol, 2011. **137**(9): p. 1337-42.
51. Butts, C., et al., *Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial*. Lancet Oncol, 2014. **15**(1): p. 59-68.
52. Tecemotide Following Concurrent Chemo-radiotherapy for Non-small Cell Lung Cancer (START2) <http://clinicaltrials.gov/ct2/show/NCT02049151>.
53. Cancer Vaccine Study for Stage III, Unresectable, Non-small Cell Lung Cancer (NSCLC) in the Asian Population (INSPIRE) <http://clinicaltrials.gov/show/NCT01015443>.
54. Pao, W. and V.A. Miller, *Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions*. J Clin Oncol, 2005. **23**(11): p. 2556-68.
55. Merlo, V., et al., *EGFR pathway in advanced non-small cell lung cancer*. Front Biosci (Schol Ed), 2011. **3**: p. 501-17.
56. Rodriguez, P.C., et al., *Clinical development and perspectives of CIMAvax EGF, Cuban vaccine for non-small-cell lung cancer therapy*. MEDICC Rev, 2010. **12**(1): p. 17-23.
57. Neningen Vinageras, E., et al., *Phase II randomized controlled trial of an epidermal growth factor vaccine in advanced non-small-cell lung cancer*. J Clin Oncol, 2008. **26**(9): p. 1452-8.
58. Vaccine Therapy in Treating Patients With Non-Small Cell Lung Cancer (NSCLC) Stages IIB/IV. <http://clinicaltrials.gov/show/NCT00516685>.
59. Rochlitz, C., et al., *Phase I immunotherapy with a modified vaccinia virus (MVA) expressing human MUC1 as antigen-specific immunotherapy in patients with MUC1-positive advanced cancer*. J Gene Med, 2003. **5**(8): p. 690-9.
60. Ramlau, R., et al., *A phase II study of Tg4010 (Mva-Muc1-II2) in association with chemotherapy in patients with stage III/IV Non-small cell lung cancer*. J Thorac Oncol, 2008. **3**(7): p. 735-44.
61. Quoix, E., et al., *Therapeutic vaccination with TG4010 and first-line chemotherapy in advanced non-small-cell lung cancer: a controlled phase 2B trial*. Lancet Oncol, 2011. **12**(12): p. 1125-33.
62. Quoix, E.A., et al., *TIME: A phase IIb/III randomized, double-blind, placebo-controlled study comparing first-line therapy with or without TG4010 immunotherapy product in patients with stage IV non-small cell lung cancer (NSCLC)*. ASCO Meeting Abstracts, 2012. **30**(15\_suppl): p. TPS7610.


63. Phase IIB/III Of TG4010 Immunotherapy In Patients With Stage IV Non-Small Cell Lung Cancer (TIME) <http://clinicaltrials.gov/show/NCT01383148>.
64. Lopez, P.H. and R.L. Schnaar, *Gangliosides in cell recognition and membrane protein regulation*. *Curr Opin Struct Biol*, 2009. **19**(5): p. 549-57.
65. van Crujisen, H., et al., *Tissue micro array analysis of ganglioside N-glycolyl GM3 expression and signal transducer and activator of transcription (STAT)-3 activation in relation to dendritic cell infiltration and microvessel density in non-small cell lung cancer*. *BMC Cancer*, 2009. **9**: p. 180.
66. Diaz, Y., et al., *Anti-ganglioside anti-idiotypic monoclonal antibody-based cancer vaccine induces apoptosis and antiangiogenic effect in a metastatic lung carcinoma*. *Cancer Immunol Immunother*, 2009. **58**(7): p. 1117-28.
67. Segatori, V.I., et al., *Preclinical evaluation of racotumomab, an anti-idiotypic monoclonal antibody to N-glycolyl-containing gangliosides, with or without chemotherapy in a mouse model of non-small cell lung cancer*. *Front Oncol*, 2012. **2**: p. 160.
68. Alfonso, S., et al., *1E10 anti-idiotypic vaccine in non-small cell lung cancer: experience in stage IIIb/IV patients*. *Cancer Biol Ther*, 2007. **6**(12): p. 1847-52.
69. Immunotherapy With Racotumomab in Advanced Lung Cancer <http://clinicaltrials.gov/ct2/show/NCT01460472>.
70. Gail, M.H., *A placebo-controlled randomized double-blind study of adjuvant intrapleural BCG in patients with resected T1N0, T1N1, or T2N0 squamous cell carcinoma, adenocarcinoma, or large cell carcinoma of the lung*. *LCSG Protocol 771*. *Chest*, 1994. **106**(6 Suppl): p. 287s-292s.
71. O'Brien, M.E., et al., *A randomized phase II study of SRL172 (Mycobacterium vaccae) combined with chemotherapy in patients with advanced inoperable non-small-cell lung cancer and mesothelioma*. *Br J Cancer*, 2000. **83**(7): p. 853-7.
72. Manegold, C., et al., *A phase III randomized study of gemcitabine and cisplatin with or without PF-3512676 (TLR9 agonist) as first-line treatment of advanced non-small-cell lung cancer*. *Ann Oncol*, 2012. **23**(1): p. 72-7.
73. Hirsh, V., et al., *Randomized phase III trial of paclitaxel/carboplatin with or without PF-3512676 (Toll-like receptor 9 agonist) as first-line treatment for advanced non-small-cell lung cancer*. *J Clin Oncol*, 2011. **29**(19): p. 2667-74.
74. Spadaro, M., et al., *Lactoferrin, a major defense protein of innate immunity, is a novel maturation factor for human dendritic cells*. *FASEB J*, 2008. **22**(8): p. 2747-57.
75. Hayes, T.G., et al., *Effect of oral talactoferrin (TLF) on levels of cytokines involved in the Th1-mediated immune response in clinical studies*. *ASCO Meeting Abstracts*, 2008. **26**(15\_suppl): p. 3080.
76. Parikh, P.M., et al., *Randomized, Double-Blind, Placebo-Controlled Phase II Study of Single-Agent Oral Talactoferrin in Patients With Locally Advanced or*

- Metastatic Non–Small-Cell Lung Cancer That Progressed After Chemotherapy.* Journal of Clinical Oncology, 2011. **29**(31): p. 4129-4136.
77. Digumarti, R., et al., *A randomized, double-blind, placebo-controlled, phase II study of oral talactoferrin in combination with carboplatin and paclitaxel in previously untreated locally advanced or metastatic non-small cell lung cancer.* J Thorac Oncol, 2011. **6**(6): p. 1098-103.
  78. Ramalingam, S., et al., *Talactoferrin alfa versus placebo in patients with refractory advanced non-small-cell lung cancer (FORTIS-M trial).* Ann Oncol, 2013. **24**(11): p. 2875-80.
  79. Kavanagh, B., et al., *CTLA4 blockade expands FoxP3+ regulatory and activated effector CD4+ T cells in a dose-dependent fashion.* Blood, 2008. **112**(4): p. 1175-83.
  80. Maker, A.V., P. Attia, and S.A. Rosenberg, *Analysis of the cellular mechanism of antitumor responses and autoimmunity in patients treated with CTLA-4 blockade.* J Immunol, 2005. **175**(11): p. 7746-54.
  81. Hodi, F.S., et al., *Improved survival with ipilimumab in patients with metastatic melanoma.* N Engl J Med, 2010. **363**(8): p. 711-23.
  82. Robert, C., et al., *Ipilimumab plus dacarbazine for previously untreated metastatic melanoma.* N Engl J Med, 2011. **364**(26): p. 2517-26.
  83. Lynch, T.J., et al., *Ipilimumab in Combination With Paclitaxel and Carboplatin As First-Line Treatment in Stage IIIB/IV Non–Small-Cell Lung Cancer: Results From a Randomized, Double-Blind, Multicenter Phase II Study.* Journal of Clinical Oncology, 2012. **30**(17): p. 2046-2054.
  84. Reck, M., et al., *Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial.* Ann Oncol, 2013. **24**(1): p. 75-83.
  85. Reck, M., et al., *CA184-104: Randomized, multicenter, double-blind, phase III trial comparing the efficacy of ipilimumab (Ipi) with paclitaxel/carboplatin (PC) versus placebo with PC in patients (pts) with stage IV/recurrent non-small cell lung cancer (NSCLC) of squamous histology.* ASCO Meeting Abstracts, 2013. **31**(15\_suppl): p. TPS8117.
  86. Von Pawel, J., et al., *CA184-156: Randomized, multicenter, double-blind, phase III trial comparing the efficacy of ipilimumab (Ipi) plus etoposide/platinum (EP) versus placebo plus EP in patients (Pts) with newly diagnosed extensive-stage disease small cell lung cancer (ED-SCLC).* ASCO Meeting Abstracts, 2013. **31**(15\_suppl): p. TPS7608.
  87. Keir, M.E., et al., *PD-1 and its ligands in tolerance and immunity.* Annu Rev Immunol, 2008. **26**: p. 677-704.
  88. Jin, H.T., R. Ahmed, and T. Okazaki, *Role of PD-1 in regulating T-cell immunity.* Curr Top Microbiol Immunol, 2011. **350**: p. 17-37.


89. Topalian, S.L., et al., *Safety, activity, and immune correlates of anti-PD-1 antibody in cancer*. N Engl J Med, 2012. **366**(26): p. 2443-54.
90. Brahmer JR, H.L., Antonia SJ, et al., *Nivolumab (anti-PD-1; BMS-936558; ONO-4538) in patients with non-small cell lung cancer (NSCLC): overall survival and long-term safety in a phase 1 trial*. Abstract MO18.03 presented at the 15th International Association for the Study of Lung Cancer World Conference on Lung Cancer, October 27–30, 2013, Sydney, Australia.
91. Bristol-Myers Squibb. Study of BMS-936558 (Nivolumab) Compared to Docetaxel in Previously Treated Advanced or Metastatic Squamous Cell Non-small Cell Lung Cancer (NSCLC) (CheckMate 017). Available from: <http://clinicaltrials.gov/show/NCT01642004>.
92. Bristol-Myers Squibb. Study of BMS-936558 (Nivolumab) Compared to Docetaxel in Previously Treated Metastatic Non-squamous NSCLC (CheckMate 057). Available from: <http://clinicaltrials.gov/show/NCT01673867>.
93. Bristol-Myers Squibb. Study of Nivolumab (BMS-936558) in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) (CheckMate 012). Available from: <http://clinicaltrials.gov/show/NCT01454102>.
94. Bristol-Myers Squibb. Study of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Squamous Cell Non-Small Cell Lung Cancer Who Have Received At Least Two Prior Systemic Regimens (CheckMate 063). Available from: <http://clinicaltrials.gov/show/NCT01721759>.
95. Sidney Kimmel Comprehensive Cancer Center. Phase II Anti-PD1 Epigenetic Priming Study in NSCLC. (NA\_00084192). Available from: <http://clinicaltrials.gov/show/NCT01928576>. NLM identifier: NCT01928576.
96. Hamid, O., et al., *Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma*. N Engl J Med, 2013. **369**(2): p. 134-44.
97. Garon EB, B.A., Hamid O, et al., *Preliminary clinical safety and activity of MK-3475 monotherapy for the treatment of previously treated patients with non-small cell lung cancer (NSCLC)*. Abstract MO18.02 presented at the 15th International Association for the Study of Lung Cancer World Conference on Lung Cancer, October 27–30, 2013, Sydney, Australia.
98. Merck. Study of Two Doses of MK-3475 Versus Docetaxel in Previously-Treated Participants With Non-Small Cell Lung Cancer (MK-3475-010). Available from: <http://clinicaltrials.gov/show/NCT01905657>.
99. Merck. A Study of MK-3475 in Combination With Chemotherapy or Immunotherapy in Participants With Lung Cancer (MK-3475-021/KEYNOTE-021) Available from: <http://clinicaltrials.gov/show/NCT02039674>.
100. Grosso, J., et al., *Programmed death-ligand 1 (PD-L1) expression in various tumor types*. Journal for ImmunoTherapy of Cancer, 2013. **1**(Suppl 1): p. P53.

101. Sznol, M. and L. Chen, *Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer*. Clin Cancer Res, 2013. **19**(5): p. 1021-34.
102. Brahmer, J.R., et al., *Safety and activity of anti-PD-L1 antibody in patients with advanced cancer*. N Engl J Med, 2012. **366**(26): p. 2455-65.
103. Nakanishi, J., et al., *Overexpression of B7-H1 (PD-L1) significantly associates with tumor grade and postoperative prognosis in human urothelial cancers*. Cancer Immunol Immunother, 2007. **56**(8): p. 1173-82.
104. Nomi, T., et al., *Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer*. Clin Cancer Res, 2007. **13**(7): p. 2151-7.
105. Thompson, R.H., et al., *Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up*. Cancer Res, 2006. **66**(7): p. 3381-5.
106. Mu, C.Y., et al., *High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation*. Med Oncol, 2011. **28**(3): p. 682-8.
107. Horn L, H.R., Spigel DR, et al. , *An analysis of the relationship of clinical activity to baseline EGFR status, PD-L1 expression and prior treatment history in patients with non-small cell lung cancer (NSCLC) following PD-L1 blockade with MPDL3280A (anti-PDL1)*. Abstract MO18.01 presented at the 15th International Association for the Study of Lung Cancer World Conference on Lung Cancer, October 27–30, 2013, Sydney, Australia.
108. A Phase 1b Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) in Combination With Tarceva in Patients With Non-Small Cell Lung Cancer <http://clinicaltrials.gov/show/NCT02013219>.
109. A Phase 2 Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) in Patients With PD-L1 Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer - "FIR" <http://clinicaltrials.gov/show/NCT01846416>.
110. A Phase 2 Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) in Patients With PD-L1 Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer - "BIRCH" <http://clinicaltrials.gov/show/NCT02031458>.
111. A Randomized Phase 2 Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) Compared With Docetaxel in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Platinum Therapy - "POPLAR" <http://clinicaltrials.gov/show/NCT01903993>.

**Figure 1.** This image represents the immunoeediting process that can be described by the three "E": Elimination, Equilibrium and Escape. In the elimination phase innate and adaptive immune systems work to eradicate the tumor cells. Tumor cells undergo to several changes and some cell variants could survive to the elimination phase and enters to the equilibrium phase. Finally tumor cells enter in to the escape phase where different mechanisms lead to tumor growth and immune evasion.




**Figure 2.** Whole cells vaccines are composed by manipulated tumor cells that induce the immune system to react against tumor. Belagenpumatucel-L (A) is produced with four cells lines representing three different histologic types of NSCLC (large cell carcinoma, squamous cell carcinoma, and adenocarcinoma) transfected with a plasmid containing TGF- $\beta$ 2 antisense transgene. The downregulation of TGF- $\beta$ , considered as an anti-inflammatory cytokine, determines the activation of NK cells, CTLs, and APC-cells and CD4+ T cells. GVAX (B) is a gene therapy vaccine. GM-CSF gene is transfected in tumor cells that are inoculated in the patient after lethal irradiation. Secretion of GM-CSF by genetically modified tumor cells stimulates cytokine release at the vaccine site to activate antigen-presenting cells, which prime CD4+ and CD8+ T cells to recognize circulating tumor-associated antigens.



**Figure 3.** Another approach to induce immune response against cancer cells is to increase the immunogenicity of tumor-associated antigen (TAA). Protein or peptide based vaccine (A) (as MAGE-A3, Tecemotide and CIMAVax) are recombinant proteins obtained by the fusion of TAA with an immunoadjuvant that is usually the immunogenic component of a virus or a bacterium. TG4010 is a viral vector vaccine (B) composed by a modified Ankara virus that expresses MUC-1 antigen and IL-2 gene. Racotumomab, is an anti-NeuGc-containing gangliosides anti-idiotype monoclonal antibody (C) that induces a strong specific cellular and humoral response against NeuGc. Dendritic cells are responsible for the antigen processing and the presentation to T cells through the interaction between MHC and T cell receptor (TCR). In order to achieve T cells activation this first signal has to be followed by a second, costimulatory signal, mediated by B7 and CD28 interaction.

## TUMOR-ASSOCIATED ANTIGEN BASED VACCINES



**Figure 4.** Immune system is able to inhibit self-reaction by means of several inhibitory receptors. Some examples of these receptors are CTLA-4 and PD-1. When CTLA-4 interacts with B7 T cells are not appropriately stimulated and enter in an anergic state. Ipilimumab (on the right) is able to block this mechanism thereby determining T cells activation. PD-1 receptor elicits T cells inactivation by interacting with its ligand PDL-1. Tumor cells are able to overexpress PDL-1 enhancing the immunescape. Therefore anti-PD1 and anti-PDL1 drugs exert their action by decoying receptor and ligand, respectively.

